We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Fujifilm SonoSite to Develop AI-Powered Ultrasound Solutions

By LabMedica International staff writers
Posted on 22 Aug 2019
FUJIFILM SonoSite, Inc. More...
(Seattle, WA, USA) has entered into a strategic relationship with Partners HealthCare (Boston, MA, USA) to apply artificial intelligence (AI) for improving the utility and functionality of portable ultrasound. The two organizations will collaborate for enhancing ultrasound technology with AI in order to enable clinicians to perform scans at the point-of-care (POC), further expanding the accessibility of this technology for clinicians and their patients. The collaboration will be executed through the MGH & BWH Center for Clinical Data Science and leverage the extensive data assets, computational infrastructure and clinical expertise of the Partners HealthCare system.

FUJIFILM SonoSite is an innovator and leader in bedside and POC ultrasound, and an industry leader in ultra high-frequency micro-ultrasound technology. Partners HealthCare is an integrated health system founded by Brigham and Women’s Hospital and Massachusetts General Hospital. In addition to its two academic medical centers, the Partners system includes community and specialty hospitals, a managed care organization, community health centers, a physician network, home health and long-term care services, and other health-related entities. The MGH & BWH Center for Clinical Data Science is a joint center formed by Massachusetts General Hospital and Brigham and Women’s Hospital to transform healthcare by translating the latest advances in AI into improved health outcomes and greater operational efficiency.

Both FUJIFILM SonoSite and Partners HealthCare agree that high fidelity, affordable medical imaging could have an impact on a global scale, particularly in the developing world, where access to care is a fundamental challenge. As an important diagnostic tool in the fields of obstetrics and emergency medicine, increased accessibility to, and utilization of, point-of-care ultrasound holds substantial promise. Through the collaboration, the collective clinical and technical expertise of the organizations will be harnessed to advance the field of POC ultrasound. The first project under the collaboration will target some of the more complex emergency medicine procedures using AI enabled portable ultrasound.

“If we build scanners that can be used by non-expert users both inside and outside the hospital, we can likely reduce the time delay between trauma and diagnosis, which will translate to more rapid interventions and improved outcomes,” said Andrew Liteplo, MD, MGH Department of Emergency Medicine.

“Allowing for even greater integration of ultrasound into our healthcare delivery system requires smarter machines,” said Keith Dreyer, DO, PhD, FACR, FSIIM, Chief Data Science Officer, Partners HealthCare. “In emergency settings, the efficiency and cost-effectiveness of portable ultrasound makes it a critical companion to other imaging modalities.”

“This collaboration is really focused on embedding AI in portable ultrasound with the goal of automating the segmentation of organ boundaries, measurement of anatomic features and calculation of physiological parameters—the type of automation that will allow us to increase the accessibility of this critical technology while still delivering high diagnostic value,” said Diku Mandavia, MD, FACEP, FRCPC, Senior Vice President and Chief Medical Officer of FUJIFILM SonoSite.

“FUJIFILM SonoSite introduced ultrasound systems designed for use at the point of care to the healthcare system over 20 years ago. We have always listened carefully to our customers to ensure their needs are being met and I am proud that we will be able to offer them AI enhanced technology to expand their utilization of ultrasound, increasing the quality of care they can provide while saving our healthcare system money,” said Rich Fabian, President and Chief Operating Officer of FUJIFILM SonoSite.



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Automatic Hematology Analyzer
CF9600
New
Next-Generation Sequencing Platform
AXELIOS 1 Platform
Thyroid Test
Anti-Thyroid EIA Test
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Tracking blood test trends alongside unexplained weight loss may help identify patients at increased cancer risk and support earlier investigation (Image Credit: 123RF)

Blood Test Patterns Improve Cancer Risk Assessment in Primary Care

Unexplained weight loss is a common but nonspecific presentation in primary care that can precede several types of cancer, making referral decisions difficult. Routine blood tests may produce borderline... Read more

Molecular Diagnostics

view channel
Image: NTM are about 200 environmental bacteria found in soil and water that can cause chronic, tuberculosis-like lung infections but are distinct from the Mycobacterium tuberculosis complex (Image Credit: Adobe Stock)

Rapid CRISPR Test Identifies Nontuberculous Mycobacteria Species from Respiratory Samples

Chronic lung infections caused by nontuberculous mycobacteria (NTM) are increasingly recognized but frequently mistaken for tuberculosis, complicating diagnosis and care. These infections may affect as... Read more

Immunology

view channel
Image: Although many people harbor latent Epstein-Barr virus (EBV), growing evidence has linked the virus to MS pathobiology (Image Credit: Adobe Stock)

Blood EBV Activity Biomarkers May Predict Multiple Sclerosis Relapse Months Ahead

Predicting relapse in multiple sclerosis (MS) remains difficult, limiting opportunities for timely intervention and monitoring. Although many people harbor latent Epstein-Barr virus (EBV), growing evidence... Read more

Microbiology

view channel
Image: Graphical Abstract (Jose A. Céspedes, Maria I. Montañez, Isabel M. Jiménez, et al. Magnetic nanoparticles enable clinically relevant in vitro diagnosis of beta-lactam allergy. Materials Today Bio (2026). DOI: 10.1016/j.mtbio.2026.103356)

Magnetic Nanoparticles Enable More Sensitive Beta-Lactam Allergy Testing

Penicillin allergy labels are common in clinical practice, yet many are incorrect and can lead to suboptimal antibiotic choices. Although 8%–25% of people report a penicillin allergy, only 1%–10% are truly... Read more

Pathology

view channel
Image Credit: Adobe Stock

Machine Learning Cytology Tool Improves Cancer Cell Identification

Cytological screening remains central to early cancer detection, but its accuracy depends heavily on expert interpretation of stained cells. Under conventional microscopy, malignant and reactive cells... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more

Industry

view channel
Image: The acquisition adds Convergent Genomics’ UroAmp platform and proprietary urinary tumor DNA technology to Veracyte’s portfolio (Photo courtesy of Convergent Genomics)

Veracyte Acquisition Expands Urine-Based Bladder Cancer Monitoring Capabilities

Veracyte, Inc. has acquired Convergent Genomics, expanding its urology diagnostics offerings with the company’s UroAmp platform and proprietary urinary tumor DNA (utDNA) technology. UroAmp has been clinically... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.